

FRESENIUS

Operating companies



Ownership: 100%

Medical devices for infusion, transfusion, and clinical nutrition

Revenue 2022: €7.9 bn



Ownership: 100%

Europe's leading private healthcare provider

Revenue 2022: €11.7 bn



Ownership: 32%

Products and services for kidney patients

Revenue 2022: €19.4 bn



Ownership: 77%

Projects and services for healthcare facilities

Revenue 2022: €2.4 bn

As of December 2023

Deconsolidation of Fresenius Medical Care completed on November 30, 2023